Cargando…

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry

OBJECTIVES: The benefit of intravenous recombinant tissue plasminogen activator (rt-PA) therapy for very old patients with acute ischemic stroke remains unclear. The aim of this study was to elucidate the efficacy and safety of intravenous rt-PA therapy for patients over 80 years old. METHODS: Of 13...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuo, Ryu, Kamouchi, Masahiro, Fukuda, Haruhisa, Hata, Jun, Wakisaka, Yoshinobu, Kuroda, Junya, Ago, Tetsuro, Kitazono, Takanari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199731/
https://www.ncbi.nlm.nih.gov/pubmed/25329379
http://dx.doi.org/10.1371/journal.pone.0110444
_version_ 1782339965724655616
author Matsuo, Ryu
Kamouchi, Masahiro
Fukuda, Haruhisa
Hata, Jun
Wakisaka, Yoshinobu
Kuroda, Junya
Ago, Tetsuro
Kitazono, Takanari
author_facet Matsuo, Ryu
Kamouchi, Masahiro
Fukuda, Haruhisa
Hata, Jun
Wakisaka, Yoshinobu
Kuroda, Junya
Ago, Tetsuro
Kitazono, Takanari
author_sort Matsuo, Ryu
collection PubMed
description OBJECTIVES: The benefit of intravenous recombinant tissue plasminogen activator (rt-PA) therapy for very old patients with acute ischemic stroke remains unclear. The aim of this study was to elucidate the efficacy and safety of intravenous rt-PA therapy for patients over 80 years old. METHODS: Of 13,521 stroke patients registered in the Fukuoka Stroke Registry in Japan from June 1999 to February 2013, 953 ischemic stroke patients who were over 80 years old, hospitalized within 3 h of onset, and not treated with endovascular therapy were included in this study. Among them, 153 patients were treated with intravenous rt-PA (0.6 mg/kg). For propensity score (PS)-matched case-control analysis, 148 patients treated with rt-PA and 148 PS-matched patients without rt-PA therapy were selected by 1∶1 matching with propensity for using rt-PA. Clinical outcomes were neurological improvement, good functional outcome at discharge, in-hospital mortality, and hemorrhagic complications (any intracranial hemorrhage [ICH], symptomatic ICH, and gastrointestinal bleeding). RESULTS: In the full cohort of 953 patients, rt-PA use was associated positively with neurological improvement and good functional outcome, and negatively with in-hospital mortality after adjustment for multiple confounding factors. In PS-matched case-control analysis, patients treated with rt-PA were still at lower risk for unfavorable clinical outcomes than non-treated patients (neurological improvement, odds ratio 2.67, 95% confidence interval 1.61–4.40; good functional outcome, odds ratio 2.23, 95% confidence interval 1.16–4.29; in-hospital mortality, odds ratio 0.30, 95% confidence interval 0.13–0.65). There was no significant association between rt-PA use and risk of hemorrhagic complications in the full and PS-matched cohorts. CONCLUSIONS: Intravenous rt-PA therapy was associated with improved clinical outcomes without significant increase in risk of hemorrhagic complications in very old patients (aged>80 years) with acute ischemic stroke.
format Online
Article
Text
id pubmed-4199731
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41997312014-10-21 Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry Matsuo, Ryu Kamouchi, Masahiro Fukuda, Haruhisa Hata, Jun Wakisaka, Yoshinobu Kuroda, Junya Ago, Tetsuro Kitazono, Takanari PLoS One Research Article OBJECTIVES: The benefit of intravenous recombinant tissue plasminogen activator (rt-PA) therapy for very old patients with acute ischemic stroke remains unclear. The aim of this study was to elucidate the efficacy and safety of intravenous rt-PA therapy for patients over 80 years old. METHODS: Of 13,521 stroke patients registered in the Fukuoka Stroke Registry in Japan from June 1999 to February 2013, 953 ischemic stroke patients who were over 80 years old, hospitalized within 3 h of onset, and not treated with endovascular therapy were included in this study. Among them, 153 patients were treated with intravenous rt-PA (0.6 mg/kg). For propensity score (PS)-matched case-control analysis, 148 patients treated with rt-PA and 148 PS-matched patients without rt-PA therapy were selected by 1∶1 matching with propensity for using rt-PA. Clinical outcomes were neurological improvement, good functional outcome at discharge, in-hospital mortality, and hemorrhagic complications (any intracranial hemorrhage [ICH], symptomatic ICH, and gastrointestinal bleeding). RESULTS: In the full cohort of 953 patients, rt-PA use was associated positively with neurological improvement and good functional outcome, and negatively with in-hospital mortality after adjustment for multiple confounding factors. In PS-matched case-control analysis, patients treated with rt-PA were still at lower risk for unfavorable clinical outcomes than non-treated patients (neurological improvement, odds ratio 2.67, 95% confidence interval 1.61–4.40; good functional outcome, odds ratio 2.23, 95% confidence interval 1.16–4.29; in-hospital mortality, odds ratio 0.30, 95% confidence interval 0.13–0.65). There was no significant association between rt-PA use and risk of hemorrhagic complications in the full and PS-matched cohorts. CONCLUSIONS: Intravenous rt-PA therapy was associated with improved clinical outcomes without significant increase in risk of hemorrhagic complications in very old patients (aged>80 years) with acute ischemic stroke. Public Library of Science 2014-10-16 /pmc/articles/PMC4199731/ /pubmed/25329379 http://dx.doi.org/10.1371/journal.pone.0110444 Text en © 2014 Matsuo et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Matsuo, Ryu
Kamouchi, Masahiro
Fukuda, Haruhisa
Hata, Jun
Wakisaka, Yoshinobu
Kuroda, Junya
Ago, Tetsuro
Kitazono, Takanari
Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
title Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
title_full Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
title_fullStr Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
title_full_unstemmed Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
title_short Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
title_sort intravenous thrombolysis with recombinant tissue plasminogen activator for ischemic stroke patients over 80 years old: the fukuoka stroke registry
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199731/
https://www.ncbi.nlm.nih.gov/pubmed/25329379
http://dx.doi.org/10.1371/journal.pone.0110444
work_keys_str_mv AT matsuoryu intravenousthrombolysiswithrecombinanttissueplasminogenactivatorforischemicstrokepatientsover80yearsoldthefukuokastrokeregistry
AT kamouchimasahiro intravenousthrombolysiswithrecombinanttissueplasminogenactivatorforischemicstrokepatientsover80yearsoldthefukuokastrokeregistry
AT fukudaharuhisa intravenousthrombolysiswithrecombinanttissueplasminogenactivatorforischemicstrokepatientsover80yearsoldthefukuokastrokeregistry
AT hatajun intravenousthrombolysiswithrecombinanttissueplasminogenactivatorforischemicstrokepatientsover80yearsoldthefukuokastrokeregistry
AT wakisakayoshinobu intravenousthrombolysiswithrecombinanttissueplasminogenactivatorforischemicstrokepatientsover80yearsoldthefukuokastrokeregistry
AT kurodajunya intravenousthrombolysiswithrecombinanttissueplasminogenactivatorforischemicstrokepatientsover80yearsoldthefukuokastrokeregistry
AT agotetsuro intravenousthrombolysiswithrecombinanttissueplasminogenactivatorforischemicstrokepatientsover80yearsoldthefukuokastrokeregistry
AT kitazonotakanari intravenousthrombolysiswithrecombinanttissueplasminogenactivatorforischemicstrokepatientsover80yearsoldthefukuokastrokeregistry
AT intravenousthrombolysiswithrecombinanttissueplasminogenactivatorforischemicstrokepatientsover80yearsoldthefukuokastrokeregistry